EGFR and thyroid gland carcinoma: For example, upregulation of the EGFR/ERK/AKT pathway has been observed in thyroid cancer cells with acquired LEN resistance, while co-administration of the EGFR inhibitor lapatinib has been shown to restore LEN sensitivity [32].